Overview
Diagonal Therapeutics Inc. is a stealth-stage biotechnology start-up seeking to capitalize on opportunities for antibody receptor agonists as drugs for immunology, oncology, and vascular diseases. We combine state-of-art immune repertoire mining, computational design, and protein engineering techniques to craft drug candidates that invoke the desired aspects of the natural ligand pharmacology, bypass native inhibitory mechanisms, and deliver a sustained activation signal to the disease-relevant cell types. We are backed by Atlas Venture and are operated by a dynamic, focused team of biologics R&D experts.